This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose
(MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and
pharmacokinetic (PK) profile of ABBV-621 for participants with previously treated solid
tumors or hematologic malignancies.
- Must have a diagnosis of a solid tumor (except primary brain tumors), acute myeloid
leukemia (AML), or non-Hodgkin lymphoma (NHL); NHL may be of any subtype for Dose
Escalation but is limited to diffuse large B-cell lymphoma (DLBCL) for those enrolled
to the cohort evaluating the combination of ABBV-621 and venetoclax. Participants in
the Dose Optimization solid tumor cohorts must have either colorectal cancer with
documented KRAS mutations (as determined by local testing), or pancreatic cancer
(irrespective of mutational status). Participants in the chemotherapy combination
cohorts must have metastatic or advanced unresectable colorectal cancer with
documented RAS mutations (as determined by local testing).
- Participant in dose escalation or dose optimization cohort must have received at least
one prior systemic therapy, and must have relapsed or progressed after, or failed to
respond to any/all available effective therapy or therapies.
- Participant in chemotherapy cohorts with CRC must have progressed after or failed to
respond to initial systemic therapy.
- Must have measurable disease (by Response Evaluation Criteria In Solid Tumors [RECIST]
1.1 for those with solid tumors; by Lugano classification for those with NHL), except
those with AML, who must have histologically confirmed relapsed or refractory disease.
- Must agree to provide the following samples for biomarker analysis:
- All participants: archived tumor tissue (if available).
- Participants in Dose Optimization (excluding AML): pre- and on-treatment fresh
tissue biopsies. (Note: fresh tissue biopsies will be optional for participants
with solid tumor or NHL in Dose Escalation and will be collected only if consent
- All participants with AML: pre- and on-treatment bone marrow aspirates (BMA)
- Participants in chemotherapy combination cohorts: participants must provide a
fresh biopsy if an archival biopsy is not available
- Must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 - 2.
Participants in chemotherapy combination cohorts must have ECOG Performance Score of 0
- Must have adequate hematologic, renal and hepatic function.
- Participants with history of brain metastases who have not shown clinical and
radiographic stable disease for at least 28 days after definitive therapy. In
addition, any AML participant identified through cerebrospinal fluid (CSF) analysis,
as having active central nervous system (CNS) disease, will be excluded.
- Presence of primary hepatobiliary malignancy, including cholangiocarcinoma or
hepatocellular carcinoma, gallbladder carcinoma, cancer of ampulla of Vater.
- Receipt of any systemic anti-cancer agent, including investigational anti-cancer
products, within 21 days prior to study drug administration or 3 half-lives, whichever
- Participant with a history of cirrhosis or other indication of significant possible
hepatic dysfunction. Note: Those with non-alcoholic steatohepatitis (NASH) should be
discussed with the AbbVie TA MD before enrollment.
- Participant with a positive diagnosis of hepatitis A, B, or C.
- Dose Optimization combination cohorts only: Prior receipt, at any time, of a BCL-2
- Dose Optimization combination cohorts only: Receipt of strong or moderate CYP3A
inducers within 7 days prior to start of study treatment or strong or moderate CYP3A
inhibitors within 3 days prior to start of study treatment.
- Dose Optimization combination cohorts only: Participant has malabsorption syndrome or
other condition that precludes enteral route of administration.
- Dose Optimization combination cohorts only: Participant has promyelocytic leukemia
- CRC chemotherapy cohort only: Participant with minor surgical procedures, such as fine
needle aspirations or core biopsies, within 7 days prior to first dose of study drug
- Participants in CRC chemotherapy combination cohort only: cardiomyopathy,
coronary/peripheral artery bypass graft, aneurysm or aneurysm repair, angioplasty,
pulmonary hypertension, cerebrovascular accident or transient ischemic attack, within
1 year of first dose of study drug.
- Chemotherapy combination CRC participants only: Prior receipt of an irinotecan-based
- Chemotherapy combination CRC participants only: Disease progression within 3-months of
initiating first-line therapy.
- Chemotherapy combination CRC participants only: history of Gilbert's syndrome or
- Chemotherapy Combination CRC Participants Only: Clinically significant conditions that
may place the participant at higher risk with anti-angiogenic therapy.